Manufactures and sells angiographic guidewires and catheters. Produces vascular closure devices and PTCA balloon catheters. Now — the numbers.
This is an established company with proven profits.
Average growth of 14% a year over the last 4 years. Every year shown ended in profit.
The market pays 23× for every dollar of annual profit — around what a business like this usually costs.
No analyst target is on record for this company.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Trading Liquidity: The shares change hands too rarely for smooth trading.
The stock trades 38% below its peak. The market has trimmed its expectations for the company.
Over the last 4 years, sales grew about 14% a year on average.
It pays out $0.18 per share each year — regular cash for whoever holds the stock.
Getting in and out without moving the price could prove difficult. Council score: 2/10.
Since the drop from its peak, buyer appetite hasn’t come back. Council score: 3/10.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: the revenue breakdown.